Alternative Cancer Treatment, Cancer Treatment, Cancer Vaccine, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Test on New Drug that Contains Cancer Cell Metastasis

Tests on New Drugs That May Provide Better Treatment
Tests on a New Drug That May Contain the Spread of Cancer

At Issels®, our immunotherapy for cancer treatments are often used with patients whose tumors have spread to other parts of the body. Over the last few years, an international research team has made significant progress in developing a drug that limits the movement of cancer cells.

Stopping the Spread of Cancer Cells

Metastasis is the term for the ability of cancer cells to move throughout the body and establish tumors in locations away from the primary site. Once a tumor metastasizes, it presents a greater challenge for successful treatment.

While cancer research primarily focuses on treating tumors directly, a multinational team of scientists decided to investigate possible methods of interfering with cancer cells’ motility. If migration could be contained, it would help prevent tumors from entering later, hard-to-treat stages.

KBU2046: Putting the Brakes on Metastasis

In 2011, the team identified a drug called KBU2046 that binds to heat-shock proteins found in all cells, preventing cell movement. Original testing was done on human cell models of breast, prostate, lung and colon cancer in vitro.

The team’s most recent study, published in June, extended testing to mouse models. Scientists were able to confirm that KBU2046 targeted cancer cells only, sparing healthy tissue, and further refinements eliminated any side effects.

The researchers believe that the positive results justify their unorthodox approach. Next step on their agenda is obtaining funds to conduct further studies in preparation for clinical trials.

Integrative Immunotherapy Treatments for Late-Stage Cancer

Numerous patients with advanced and therapy-resistant tumors have achieved long-term remission with our personally developed immunotherapy for cancer programs. Visit our website to hear and read their first-person testimonials.

Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Special Adoptive T Cell Therapy Reprograms Metabolism of Cancer Cells Causing Their Death

New Cancer Research is Focused on T Cells
New Cancer Research is Focused on T Cells

“Everything in moderation” is often cited as the key to balance in life, but scientists are taking a different approach in a new form of cancer treatment. According to the results of a recent study, driving up levels of oxidative stress can be fatal to cancer cells.

Reprogramming the Metabolism of Cancer Cells

Reactive oxygen species (ROS) such as peroxide and superoxide are natural byproducts of the metabolism of oxygen, and they play a role in certain cell functions. But while high levels of ROS can kill normal cells and damage DNA, energy-hungry cancer cells consume greater quantities of ROS.

In a study published in Cell Metabolism, a research team at Augusta University examined the effects of adaptive T cell therapy on the metabolism of cancer cells. Testing was conducted on mice with large colorectal tumors.

When Oxidative Stress Becomes Fatal

Adoptive T cell therapy followed treatment with a chemotherapy drug that boosted the activity of the infused T cells. Nearly all the mice experienced complete tumor regression as an apparent result of two factors:

– Treatment interfered with production of an antioxidant called glutathione, causing ROS levels to rise.

– T cells increased production of proinflammatory cytokines, chief among them tumor necrosis factor alpha, making cancer cells even more vulnerable to oxidative stress.

Dr. Gang Zhou, author of the study, expressed hope that these findings will help improve immunotherapy treatments by making it easier for T cells to target tumors.

Personalized Cancer Treatment at Issels®

Our comprehensive cancer treatment programs incorporate therapies that best address a patient’s individual needs. Contact us to learn more.

Alternative Cancer Treatment, Cancer Vaccine, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Identification of Key Biological Pathway Primes Immune System to Fight Cancer

1 Comment
It's Time to Stop Cancer
It’s Time to Stop Cancer

While immunotherapy cancer treatment has provided options for many patients, doctors are challenged by determining which patients will be most receptive. The recent discovery of a key biological pathway may prove to be a useful solution.

Stimulating the Power of the Immune System

Cancer cells often avoid the normal immune response by triggering the brake mechanism that keeps T cells from attacking healthy tissue. Immunotherapy drugs called checkpoint inhibitors override the brakes, but so far this treatment has been successful with a minority of patients.

In 2014, a research team at UC San Francisco discovered an element of the immune system called stimulatory dendritic cells (SDC), which help direct T cells to a target. The scientists also uncovered a correlation between low levels of SDCs and poor response to checkpoint inhibitors.

Creating a Receptive Environment for Immunotherapy

The team recently set out to learn why SDC levels vary among tumors. In this study, they found that natural killer (NK) cells in the immune system express a signaling protein known as FLT3LG. Presence of FLT3LG has a strong relationship to presence of SDCs.

While NK cells have long been recognized as a direct threat to cancer cells, the UCSF study demonstrates that they can also communicate with other immune cells. Scientists are hopeful that developing a way to increase the number of NK cells in a tumor will help more patients benefit from immunotherapy.

Issels®: The Leader in Advanced Cancer Treatment

Issels® has been ahead of the curve with cancer treatment methods such as dendritic cell vaccines and activated NK cells. Contact us for more information.

Alternative Cancer Treatment, Cancer Research, Cancer Treatment, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer, Uncategorized

Tel Aviv University Nanoprobes Light Up Stray Cancer Cells

New Cancer Research Is Improving Cancer Treatment
New Cancer Research Is Improving Cancer Treatment

While cancer treatment often includes surgery, even a few missed cells can lead to recurrence and metastasis. Recent development of a “smart probe” that pinpoints cancer cells may greatly improve the effectiveness of surgical options.

Challenges of Surgery as Cancer Treatment

Removal of solid tumors can still leave behind stray cells that evade detection by MRI or CT. In some cases, surgeons end up damaging otherwise healthy tissue in an effort to excise all diseased cells.

Extensive studies by an interdisciplinary team at Tel Aviv University culminated in development of a nanoprobe that literally shines a light on cancer cells. When injected into a patient a few hours before surgery begins, the probe can alert the surgeon to the presence of cancer cells that might have been missed.

“Shedding a Light” on Cancer Cells

The probe is activated by the presence of an enzyme known as cysteine cathepsins, which occurs in higher numbers in tumor cells than in healthy cells. When the probe identifies cancerous cells, it triggers a fluorescent signal in those areas, while healthy tissue remains dark.

In tests conducted on mice with melanoma and breast cancer, the survival rate of mice that underwent probe-assisted surgery was double that of the mice who received regular surgery. Now that the team has registered patents for the technology, the next step is to start clinical trials with hopes of commercially marketing the probe.

Issels®: The Leader in Personally Developed Cancer Treatment

Our comprehensive cancer treatment programs incorporate a wide range of methods in order to address each patient’s individual needs. Contact us to learn more about the “Issels® Difference.”

Cancer Research, Cancer Treatment, Cancer Vaccine, Immuno-Oncology, Immunotherapy for Cancer, Uncategorized

Modified Polio Virus to be Tested In Brain Cancer Research Efforts

Issels the Premier Provider of Immuno Oncology
Issels the Premier Provider of Immuno Oncology

When it comes to your health, a virus is generally something to be avoided. In a surprising discovery, a virus that normally causes paralysis may hold promise as an immunotherapy for cancer treatment.

Can a Virus Actually Fight a Tumor?

Glioblastoma is the most common and most deadly form of brain cancer affecting adults. It gained a measure of public awareness after former Sen. Edward Kennedy and Beau Biden, son of former Vice President Joe Biden, succumbed to the disease. One year ago Sen. John McCain, already a cancer survivor, was diagnosed with glioblastoma.

Poliovirus, which causes the paralyzing disease that shares its name, infects cells in the nervous system. Based on this feature, a team of Duke University scientists decided to test a genetically modified version on patients with treatment-resistant glioblastoma.

Poliovirus and the Immune System: A Two-Pronged Attack

The researchers neutralized the virus by replacing the specific gene that causes polio with one from rhinovirus, which generally causes head colds. Once infused directly into the tumors, the newly formed virus was able to infect and kill cancer cells as well as stimulate the immune system to attack the cells.

According to team member Dr. Darell Bigner, the group’s 21 percent survival rate after three years is more than five times that of a previously treated comparison group. The researchers are planning to conduct studies combining the modified poliovirus with other immunotherapy for cancer drugs in hopes of improving the results.

Treatment for Advanced and Therapy-Resistant Cancers

Our Issels® immunotherapy for cancer programs have helped a number of patients when other treatments have failed. Contact us for more information.

Alternative Cancer Treatment, Cancer Research, Cancer Treatment, Immuno-Oncology, Immunotherapy for Cancer, Uncategorized

Should Immunotherapy be the Last Resort for Cancer Treatment?

It's Time to Cross Out Cancer! Using Immunotherapy Treatments
It’s Time to Cross Out Cancer! Using Immunotherapy Treatments

While immunotherapy for cancer has provided an exciting new avenue for scientists, there is still much to be learned about which patients will respond, leading to a serious dilemma for doctors: when all other methods have failed, is it ethical to provide cancer patients with immunotherapy treatments on an experimental basis?

If a Little Is Good, Is a Lot Better?

You need to go back only to the 1980s and 1990s for an example of the dangers of treating patients with untested methods. Many doctors began giving women with breast cancer higher-than-usual doses of chemotherapy and radiation based solely on theory, but it turned out that the treatment was worse than the disease.

Immunotherapy for cancer drugs that have received approval, such as Opdivo and Keytruda, are restricted to a narrow range of patients. Many oncologists won’t consider immunotherapy as an option outside of its designated uses.

“Desperation Oncology”: A Last Chance

Recently, though, oncologists such as Dr. Oliver Sarter of Tulane Medical Center have begun to offer what they refer to as “desperation oncology.” The reasoning is that if a cancer patient is terminal and there’s even an infinitesimal chance that an immunotherapy drug may help, it’s worth the risk.

Not surprisingly, results have been mixed. Drugs had no effect on one patient with bladder cancer who was treated by Dr. Sarter, while another patient with metastatic prostate cancer went into immediate remission upon treatment.

Tailoring Immunotherapy for Cancer to the Patient

At Issels®, we conduct a number of tests to ensure that we design a course of treatment that’s appropriate for each patient. Contact us for more information.

Individualized Cancer Treatment